Clinical Trial Studying the Efficacy and Safety of IP2018 in Depressed, Erectile Dysfunction (ED) Patients
Status:
Recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
This is a Phase IIa, randomised, double-blind, placebo-controlled, 3-period, crossover study
to assess two single oral dose levels of IP2018. It is planned to enrol 24 patients. Patients
will take part in three treatment periods, in which they will be randomised to receive either
a single dose of IP2018 or a single dose of placebo in each treatment period.